Tourmaline Bio Inc

TRML

Company Profile

  • Business description

    Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.

  • Contact

    27 West 24th Street
    Suite 702
    New YorkNY10010
    USA

    T: +1 646 481-9832

    https://www.tourmalinebio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    74

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,831.5053.600.61%
CAC 407,878.46111.751.44%
DAX 4024,549.56342.651.42%
Dow JONES (US)44,458.30217.540.49%
FTSE 1008,867.0212.840.15%
HKSE23,914.7922.470.09%
NASDAQ20,611.34192.870.94%
Nikkei 22539,616.80204.48-0.51%
NZX 50 Index12,736.6931.92-0.25%
S&P 5006,263.2637.740.61%
S&P/ASX 2008,593.7055.100.65%
SSE Composite Index3,505.5812.530.36%

Market Movers